Technical Analysis for CARA - Cara Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
23.92 | 7.75% | 1.72 |
CARA closed up 7.75 percent on Thursday, September 20, 2018, on 2.08 times normal volume. The bulls were able to push the stock to a new 52-week high. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| See historical CARA trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Sep 20 | New 52 Week Closing High | Bullish | 0.00% |
| Sep 20 | 180 Bullish Setup | Bullish Swing Setup | 0.00% |
| Sep 20 | Expansion Breakout | Bullish Swing Setup | 0.00% |
| Sep 20 | Pocket Pivot | Bullish Swing Setup | 0.00% |
| Sep 20 | New 52 Week High | Strength | 0.00% |
| Sep 20 | Stochastic Reached Overbought | Strength | 0.00% |
| Sep 20 | Upper Bollinger Band Walk | Strength | 0.00% |
| Sep 20 | Above Upper BB | Strength | 0.00% |
| Sep 20 | Overbought Stochastic | Strength | 0.00% |
| Sep 20 | Upper Bollinger Band Touch | Strength | 0.00% |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2018-08-07
- Sector: Healthcare
- Industry: Biotechnology & Medical Research
Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat pain. Its products include intravenous CR845 that has completed Phase II clinical trials for the treatment of acute postoperative pain in adult patients; Oral CR845, which is in Phase I clinical trials to treat acute and chronic pain; and CR701 that is in preclinical trials for treating neuropathic and inflammatory pain. The company was founded in 2004 and is based in Shelton, Connecticut.
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more CARA news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 24.01 |
| 52 Week Low | 11.12 |
| Average Volume | 770,629 |
| 200-Day Moving Average | 15.3809 |
| 50-Day Moving Average | 19.5898 |
| 20-Day Moving Average | 20.5015 |
| 10-Day Moving Average | 21.463 |
| Average True Range | 0.9514 |
| ADX | 27.89 |
| +DI | 33.0555 |
| -DI | 8.0111 |
| Chandelier Exit (Long, 3 ATRs ) | 21.1558 |
| Chandelier Exit (Short, 3 ATRs ) | 20.7342 |
| Upper Bollinger Band | 23.1717 |
| Lower Bollinger Band | 17.8313 |
| Percent B (%b) | 1.14 |
| BandWidth | 26.048826 |
| MACD Line | 0.9697 |
| MACD Signal Line | 0.67 |
| MACD Histogram | 0.2997 |
| Fundamentals | Value |
|---|---|
| Market Cap | 779.33 Million |
| Num Shares | 32.6 Million |
| EPS | -2.28 |
| Price-to-Earnings (P/E) Ratio | -10.49 |
| Price-to-Sales | 424.16 |
| Price-to-Book | 3.54 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 26.56 | ||||
| Resistance 3 (R3) | 26.30 | 25.15 | 26.12 | ||
| Resistance 2 (R2) | 25.15 | 24.48 | 25.29 | 25.97 | |
| Resistance 1 (R1) | 24.54 | 24.07 | 24.85 | 24.80 | 25.83 |
| Pivot Point | 23.39 | 23.39 | 23.55 | 23.53 | 23.39 |
| Support 1 (S1) | 22.78 | 22.72 | 23.09 | 23.04 | 22.01 |
| Support 2 (S2) | 21.63 | 22.31 | 21.77 | 21.87 | |
| Support 3 (S3) | 21.02 | 21.63 | 21.72 | ||
| Support 4 (S4) | 21.28 |
